A simulation model of colorectal cancer surveillance and recurrence

BMC Medical Informatics and Decision Making

Volumn 14, Issue 1, 2014, Pages

  Rose, Johnie ^a,b   Augestad, Knut Magne ^c   Kong, Chung Yin ^d   Meropol, Neal J ^a,b,e   Kattan, Michael W ^f   Hong, Qingqing ^a   An, Xuebei ^a   Cooper, Gregory S ^a,b,e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal cancer; Follow up; Model; Recurrence; Surveillance

Indexed keywords

ARTICLE; CALIBRATION; COLORECTAL TUMOR; COMPUTER SIMULATION; DISEASE COURSE; EPIDEMIOLOGICAL MONITORING; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; TUMOR RECURRENCE;

CALIBRATION; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; DISEASE PROGRESSION; EPIDEMIOLOGICAL MONITORING; HUMANS; NEOPLASM RECURRENCE, LOCAL; PATIENT OUTCOME ASSESSMENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84899487114     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-14-29     Document Type: Article

References (65)

1. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, CA Cancer J Clin 2009 59 4 225 249 10.3322/caac.20006 19474385
2. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Bohm B, Schwenk W, Hucke HP, Stock W, Dis Colon Rectum 1993 36 3 280 286 10.1007/BF02053511 8449134
3. Guidelines for follow up after resection of colorectal cancer. Scholefield JH, Steele RJ, Gut 2002 51 Suppl 5 &223 V5 12221030
4. Colorectal cancer. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N, Lancet 2010 375 9719 1030 1047 10.1016/S0140-6736(10) 60353-4 20304247
5. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD, Br J Surg 1997 84 5 666 669 10.1002/bjs.1800840523 9171758
6. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Jeffery M, Hickey BE, Hider PN, Cochrane Database Syst Rev 2007 1 D002200 17253476
7. Follow-up after curative resection of colorectal cancer: a meta-analysis. Tjandra JJ, Chan MK, Dis Colon Rectum 2007 50 11 1783 1799 10.1007/s10350-007- 9030-5 17874269
8. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C, BMC Cancer 2003 3 26 14529575
9. Cost of patient follow-up after potentially curative colorectal cancer treatment. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE, JAMA 1995 273 23 1837 1841 10.1001/jama.1995.03520470045030 7776499
10. Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Bleeker WA, Mulder NH, Hermans J, Otter R, Plukker JT, Br J Surg 2001 88 1 101 106 10.1046/j.1365-2168.2001.01638.x 11136320
11. Follow-up in colorectal cancer patients: a cost-benefit analysis. Audisio RA, Setti-Carraro P, Segala M, Capko D, Andreoni B, Tiberio G, Ann Surg Oncol 1996 3 4 349 357 10.1007/BF02305664 8790847
12. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ, J Clin Oncol 2005 23 33 8512 8519 10.1200/JCO.2005.04.0063 16260687
13. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. Engstrom PF, Arnoletti JP, 3rd Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, J Natl ComprCanc Netw 2009 7 8 838 881
14. NCCN Clinical Practice Guidelines in Oncology: colon cancer. Engstrom PF, Arnoletti JP, 3rd Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, J Natl ComprCanc Netw 2009 7 8 778 831
15. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C, Gastroenterology 2003 124 2 544 560 10.1053/gast.2003.50044 12557158
16. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Anthony T, Simmang C, Hyman N, Buie D, Kim D, Cataldo P, Orsay C, Church J, Otchy D, Cohen J, Perry WB, Dunn G, Rafferty J, Ellis CN, Rakinic J, Fleshner P, Stahl T, Gregorcyk S, Ternent C, 3rd Kilkenny JW, Whiteford M, Dis Colon Rectum 2004 47 6 807 817 10.1007/s10350-004-0519-x 15108028
17. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, Burt RW, Byers T, Fletcher RH, Hyman N, Johnson D, Kirk L, Lieberman DA, Levin TR, O'Brien MJ, Simmang C, Thorson AG, Winawer SJ, Gastroenterology 2006 130 6 1865 1871 10.1053/j.gastro.2006.03.013 16697749
18. ASGE guideline: colorectal cancer screening and surveillance. Davila RE, Rajan E, Baron TH, Adler DG, Egan JV, Faigel DO, Gan SI, Hirota WK, Leighton JA, Lichtenstein D, Qureshi WA, Shen B, Zuckerman MJ, VanGuilder T, Fanelli RD, Gastrointest Endosc 2006 63 4 546 557 10.1016/j.gie.2006.02.002 16564851
19. An interim analysis of recruitment to the COLOFOL trial. Wille-Jorgensen P, Laurberg S, Pahlman L, Carriquiry L, Lundqvist N, Smedh K, Svanfeldt M, Bengtson J, Colorectal Dis 2009 11 7 756 758 10.1111/j.1463-1318.2008.01668.x 19708095
20. University hospitals Southampton NHS Foundation Trust, Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer. The FACS study 2011 http://www.clinicaltrials.gov/ct2/show/ NCT00560365?term=FACS&rank=3
21. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Grossmann EM, Johnson FE, Virgo KS, Longo WE, Fossati R, Surg Oncol 2004 13 2-3 119 124 15572094
22. Analysis of colorectal cancer screening regimens. Clemen RT, Lacke CJ, Health Care Manag Sci 2001 4 4 257 267 10.1023/A:1011886010184 11718458
23. Cost-effectiveness of screening for colorectal cancer in the general population. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM, JAMA 2000 284 15 1954 1961 10.1001/jama.284.15.1954 11035892
24. Colorectal cancer screening: efficiency and effectiveness. Gyrd-Hansen D, Sogaard J, Kronborg O, Health Econ 1998 7 1 9 20 10.1002/(SICI)1099- 1050(199802)7:1<9::AID-HEC304>3.0.CO;2-H 9541080
25. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy. Haug U, Brenner H, Cancer Epidemiol Biomarkers Prev 2005 14 2 422 428 10.1158/1055-9965.EPI-04-0411 15734968
26. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. Lejeune C, Arveux P, Dancourt V, Fagnani F, Bonithon-Kopp C, Faivre J, Eur J Cancer Prev 2003 12 1 77 84 10.1097/00008469-200302000-00012 12548114
27. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Lejeune C, Arveux P, Dancourt V, Bejean S, Bonithon-Kopp C, Faivre J, Int J Technol Assess Health Care 2004 20 4 434 439 15609792
28. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD, Comput Biomed Res 1999 32 1 13 33 10.1006/cbmr.1998.1498 10066353
29. Cost-effectiveness of screening for colorectal cancer: a simulation model. Neilson AR, Whynes DK, IMA J Math Appl Med Biol 1995 12 3-4 355 367 8919570
30. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Song K, Fendrick AM, Ladabaum U, Gastroenterology 2004 126 5 1270 1279 10.1053/j.gastro.2004.02.016 15131787
31. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Vijan S, Hwang EW, Hofer TP, Hayward RA, Am J Med 2001 111 8 593 601 10.1016/S0002-9343(01)00977-9 11755501
32. Development of a simulation model of colorectal cancer. Roberts S, Wang L, Klein R, Neiss R, Dittus R, ACM Trans Modeling Comp Simulation 2007 18 1 4.1 4.30
33. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG, Med Decis Making 2011 31 4 530 539 10.1177/0272989X11408730 21673186
34. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. Renehan AG, O'Dwyer ST, Whynes DK, BMJ 2004 328 7431 81 10.1136/bmj.328.7431.81 14715603
35. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. Borie F, Combescure C, Daures JP, Tretarre B, Millat B, World J Surg 2004 28 6 563 569 15366746
36. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, Lester JS, Tanabe KK, Weinstein MC, Ann Surg 2003 237 4 544 555 12677152
37. Estimating the unknown parameters of the natural history of metachronous colorectal cancer using discrete-event simulation. Erenay FS, Alagoz O, Banerjee R, Cima RR, Med Decis Making 2011 31 4 611 624 10.1177/0272989X10391809 21212440
38. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A, J Clin Oncol 2007 25 29 4569 4574 10.1200/JCO.2006.10.4323 17876008
39. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Graham RA, Wang S, Catalano PJ, Haller DG, Ann Surg 1998 228 1 59 63 10.1097/00000658-199807000-00009 9671067
40. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Colon Cancer 2014 http://www.nccn.org/professionals/physician-gls/ pdf/colon.pdf
41. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP, Surg Oncol 2009 18 1 15 24 10.1016/j.suronc.2008.05.008 18619834
42. Accuracy of lung imaging in metastases with implications for the role of thoracoscopy. McCormack PM, Ginsberg KB, Bains MS, Burt ME, Martini N, Rusch VW, Ginsberg RJ, Ann Thorac Surg 1993 56 4 863 865 discussion 865-866 10.1016/0003-4975(93)90344-H 8215662
43. Pulmonary staging in colorectal cancer-is computerised tomography the answer? McIntosh J, Sylvester PA, Virjee J, Callaway M, Thomas MG, Ann R Coll Surg Engl 2005 87 5 331 333 10.1308/003588405X60579 16176690
44. Whole-body PET imaging with [18 F]fluorodeoxyglucose in management of recurrent colorectal cancer. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA, Arch Surg 1999 134 5 503 511 discussion 511-503 10.1001/archsurg.134.5.503 10323422
45. Helical CT versus CT arterial portography in the detection of hepatic metastasis of colorectal carcinoma. Valls C, Lopez E, Guma A, Gil M, Sanchez A, Andia E, Serra J, Moreno V, Figueras J, AJR Am J Roentgenol 1998 170 5 1341 1347 10.2214/ajr.170.5.9574613 9574613
46. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Valls C, Andia E, Sanchez A, Guma A, Figueras J, Torras J, Serrano T, Radiology 2001 218 1 55 60 10.1148/radiology.218.1.r01dc1155 11152779
47. Accuracy of investigations for asymptomatic colorectal liver metastases. Glover C, Douse P, Kane P, Karani J, Meire H, Mohammadtaghi S, Allen-Mersh TG, Dis Colon Rectum 2002 45 4 476 484 10.1007/s10350-004-6224-y 12006929
48. The role of contrast-enhanced ultrasound for focal liver lesion detection: an overview. Konopke R, Bunk A, Kersting S, Ultrasound Med Biol 2007 33 10 1515 1526 10.1016/j.ultrasmedbio.2007.04.009 17618038
49. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Staib L, Schirrmeister H, Reske SN, Beger HG, Am J Surg 2000 180 1 1 5 10.1016/S0002-9610(00)00406-2 11036130
50. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, Hall D, Hamlin JA, Schapiro M, O'Brien MJ, Sternberg SS, Gottlieb LS, N Engl J Med 2000 342 24 1766 1772 10.1056/NEJM200006153422401 10852998
51. World Health Organization, Life tables for WHO member states 1990 [ http://www.who.int/gho/mortality-burden-disease/life-tables/life-tables/en/ ]
52. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A, Dis Colon Rectum 1998 41 9 1127 1133 10.1007/BF02239434 9749496
53. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ, J Clin Oncol 2008 26 14 2336 2341 10.1200/JCO.2007.15.8261 18467725
54. Calibration of disease simulation model using an engineering approach. Kong CY, McMahon PM, Gazelle GS, Value Health 2009 12 4 521 529 10.1111/j.1524-4733.2008.00484.x 19900254
55. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M, Br J Cancer 2006 94 7 982 999 10.1038/sj.bjc. 6603033 16538219
56. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Pfannschmidt J, Dienemann H, Hoffmann H, Ann Thorac Surg 2007 84 1 324 338 10.1016/j.athoracsur.2007.02.093 17588454
57. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, Glimelius B, Cancer 2009 115 20 4679 4687 10.1002/cncr.24527 19562777
58. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D, Sugarbaker P, Iwatsuki S, Starzl T, Ramming KP, Longmire WP, O'Toole K, Petrelli NJ, Herrera L, Cady B, McDermott W, Nims T, Enker WE, Coppa GF, Blumgart LH, Bradpiece H, Urist M, Aldrete JS, Schlag P, Hohenberger P, Steele G, et al. Dis Colon Rectum 1988 31 1 1 4 10.1007/BF02552560 3366020
59. Hepatic resection for metastatic disease. Olak J, Wexler MJ, Rodriguez J, McLean AP, Can J Surg 1986 29 6 435 439 3779547
60. Hepatic resection for isolated metastasis from colorectal carcinoma. Petrelli NJ, Nambisan RN, Herrera L, Mittelman A, Am J Surg 1985 149 2 205 209 10.1016/S0002-9610(85)80065-9 3970316
61. The cost-effectiveness of screening for colorectal cancer. Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA, CMAJ 2010 182 12 1307 1313 10.1503/cmaj.090845 20624866
62. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Pignone M, Saha S, Hoerger T, Mandelblatt J, Ann Intern Med 2002 137 2 96 104 10.7326/0003-4819-137-2- 200207160-00007 12118964
63. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG, J Natl Cancer Inst 2010 102 16 1238 1252 10.1093/jnci/djq242 20664028
64. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M, Ann Intern Med 2010 153 6 368 377 10.7326/0003-4819-153-6-201009210-00004 20855801
65. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD, Int J Colorectal Dis 1997 12 6 329 334 10.1007/s003840050118 9457525